All News

2019

August

Media Release / Aug 29, 2019

Sandoz Inc. voluntarily recalls Losartan Potassium and Ezetimibe in prescription drug bottles in the U.S. due to failure to meet child-resistant closure requirements

Read More
Media Release / Aug 08, 2019

IMPORTANT UPDATE: Formulary wins for SYMJEPI®

Read More

June

Media Release / Jun 04, 2019

Novartis and Sandoz Honored with Power of Partnership Award

Read More

May

Media Release / May 29, 2019

Sandoz launches Fulvestrant Injection, the first generic version of FASLODEX®, in the US

Read More
Media Release / May 08, 2019

Update on SYMJEPI™ (epinephrine) in the US

Read More

January

Media Release / Jan 31, 2019

Sandoz US recognized as Top Employer for 2019

Read More
2018

November

Media Release / Nov 08, 2018

Sandoz Inc. Issues Voluntary Nationwide Recall of One Lot of Losartan Potassium and Hydrochlorothiazide Due to the Detection of Trace Amounts of NDEA (N-Nitrosodiethylamine) Impurity Found in the Active Pharmaceutical Ingredient (API)

Read More
Media Release / Nov 02, 2018

Sandoz decides not to pursue US biosimilar rituximab; will focus on robust biosimilar portfolio for unmet access and sustainability needs

Read More

October

Media Release / Oct 31, 2018

Sandoz receives US FDA approval for biosimilar Hyrimoz™ (adalimumab-adaz)

Read More
Media Release / Oct 23, 2018

Sandoz delivers positive results for proposed biosimilars adalimumab and etanercept

Read More